A. Bradway Robert's most recent trade in Boeing Co. was a trade of 424 Phantom Stock Units done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 424 | 14,635 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 86,042 | 86,042 | - | - | Nqso (Right to Buy) | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 13,311 | 413,499 (0%) | 0% | 0 | Common Stock | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.78 per share. | 02 May 2025 | 2,481 | 402,540 (0%) | 0% | 283.8 | 704,058 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.78 per share. | 02 May 2025 | 2,352 | 400,188 (0%) | 0% | 283.8 | 667,451 | Common Stock |
| Amgen | A. Bradway Robert | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 288.56 per share. | 30 Apr 2025 | 2,544 | 405,021 (0%) | 0% | 288.6 | 734,097 | Common Stock |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 529 | 14,211 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 313.71 per share. | 17 Mar 2025 | 12,853 | 587,565 (0%) | 0% | 313.7 | 4,032,115 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 25,734 | 599,925 (0%) | 0% | 0 | Common Stock | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 508 | 13,682 | - | - | Phantom Stock Units | |
| Amgen | Bradway A. Robert | Director, Chairman, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2024 | 96,000 | 573,855 (0%) | 0% | 0 | Common Stock | |
| Amgen | A. Robert Bradway | Director, Chairman, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2024 | 90,000 | 90,000 (0%) | 0% | 0 | Common Stock | |
| Amgen | Bradway Robert A. | Director, Chairman, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2024 | 90,000 | 393,855 (0%) | 0% | 0 | Common Stock | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 580 | 13,173 | - | - | Phantom Stock Units | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 479 | 12,593 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 77,877 | 77,877 | - | - | Nqso (Right to Buy) | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 11,988 | 669,269 (0%) | 0% | 0 | Common Stock | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 311.29 per share. | 05 May 2024 | 2,220 | 657,281 (0%) | 0% | 311.3 | 691,064 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 277.37 per share. | 02 May 2024 | 2,294 | 659,501 (0%) | 0% | 277.4 | 636,287 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 276.38 per share. | 30 Apr 2024 | 2,282 | 661,795 (0%) | 0% | 276.4 | 630,699 | Common Stock |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 464 | 12,113 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 268.87 per share. | 18 Mar 2024 | 20,560 | 664,077 (0%) | 0% | 268.9 | 5,527,967 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 41,133 | 683,910 (0%) | 0% | 0 | Common Stock | |
| Boeing | Bradway A. Robert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 348 | 11,648 | - | - | Phantom Stock Units | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2023 | 467 | 11,300 | - | - | Phantom Stock Units | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 420 | 10,832 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 231.89 per share. | 05 May 2023 | 2,083 | 641,734 (0%) | 0% | 231.9 | 483,027 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 114,040 | 114,040 | - | - | Nqso (Right to Buy) | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 13,486 | 646,680 (0%) | 0% | 0 | Common Stock | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.97 per share. | 02 May 2023 | 2,863 | 643,817 (0%) | 0% | 236.0 | 675,582 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.74 per share. | 30 Apr 2023 | 2,208 | 633,194 (0%) | 0% | 239.7 | 529,346 | Common Stock |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 411 | 10,412 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 234.57 per share. | 17 Mar 2023 | 13,971 | 635,402 (0%) | 0% | 234.6 | 3,277,177 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 27,915 | 648,712 (0%) | 0% | 0 | Common Stock | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 455 | 10,000 | - | - | Phantom Stock Units | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 715 | 9,544 | - | - | Phantom Stock Units | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 640 | 8,829 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 236.10 per share. | 05 May 2022 | 2,017 | 619,841 (0%) | 0% | 236.1 | 476,214 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 112,508 | 112,508 | - | - | Nqso (Right to Buy) | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 13,781 | 624,550 (0%) | 0% | 0 | Common Stock | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 230.92 per share. | 02 May 2022 | 2,692 | 621,858 (0%) | 0% | 230.9 | 621,637 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 249.87 per share. | 27 Apr 2022 | 2,547 | 610,769 (0%) | 0% | 249.9 | 636,419 | Common Stock |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 465 | 8,189 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.86 per share. | 18 Mar 2022 | 17,481 | 613,316 (0%) | 0% | 235.9 | 4,123,069 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 34,964 | 630,141 (0%) | 0% | 0 | Common Stock | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 428 | 7,723 | - | - | Phantom Stock Units | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 396 | 7,294 | - | - | Phantom Stock Units | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 385 | 6,898 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 115,307 | 115,307 | - | - | Nqso (Right to Buy) | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 13,280 | 599,925 (0%) | 0% | 0 | Common Stock | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.64 per share. | 30 Apr 2021 | 2,902 | 597,023 (0%) | 0% | 239.6 | 695,435 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.64 per share. | 30 Apr 2021 | 2,850 | 594,173 (0%) | 0% | 239.6 | 682,974 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 255.52 per share. | 27 Apr 2021 | 2,617 | 586,645 (0%) | 0% | 255.5 | 668,696 | Common Stock |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 328 | 6,512 | - | - | Phantom Stock Units | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.42 per share. | 19 Mar 2021 | 21,190 | 589,262 (0%) | 0% | 244.4 | 5,179,260 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 38,953 | 609,806 (0%) | 0% | 0 | Common Stock | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.69 per share. | 18 Feb 2021 | 73,500 | 618,380 (0%) | 0% | 54.7 | 4,019,715 | Common Stock |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 73,500 | 0 | - | - | Nqso (Right to Buy) | |
| Amgen | Robert A. Bradway | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.61 per share. | 18 Feb 2021 | 47,527 | 570,853 (0%) | 0% | 235.6 | 11,197,836 | Common Stock |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 405 | 6,183 | - | - | Phantom Stock Units | |
| Boeing | Robert A. Bradway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 495 | 5,777 | - | - | Phantom Stock Units |